Ascendis Historical Income Statement
| ASND Stock | USD 136.08 0.24 0.18% |
Historical analysis of Ascendis Pharma income statement accounts such as Interest Expense of 46.3 M, Selling General Administrative of 277.6 M or Total Revenue of 280.1 M can show how well Ascendis Pharma AS performed in making a profits. Evaluating Ascendis Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ascendis Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Ascendis Pharma AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ascendis Pharma AS is a good buy for the upcoming year.
Ascendis |
About Ascendis Income Statement Analysis
Ascendis Pharma AS Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ascendis Pharma shareholders. The income statement also shows Ascendis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Ascendis Pharma Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Ascendis Pharma AS generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Ascendis Pharma AS minus its cost of goods sold. It is profit before Ascendis Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ascendis Pharma AS. It is also known as Ascendis Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Ascendis Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ascendis Pharma AS current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Ascendis Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 277.6 M, whereas EBIT is projected to grow to (408.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.9M | 50.5M | 44.1M | 46.3M | Depreciation And Amortization | 16.0M | 17.6M | 18.9M | 19.9M |
Ascendis Pharma income statement Correlations
Click cells to compare fundamentals
Ascendis Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ascendis Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 9.7M | 8.8M | 16.0M | 17.6M | 18.9M | 19.9M | |
| Interest Expense | 1.2M | 1.9M | 3.9M | 50.5M | 44.1M | 46.3M | |
| Selling General Administrative | 48.5M | 76.7M | 160.2M | 221.2M | 264.4M | 277.6M | |
| Total Revenue | 13.4M | 7.0M | 7.8M | 51.2M | 266.7M | 280.1M | |
| Gross Profit | 13.4M | 7.0M | 4.3M | 39.0M | 222.3M | 233.4M | |
| Other Operating Expenses | 240.1M | 337.6M | 459.6M | 613.0M | 722.3M | 758.4M | |
| Operating Income | (226.7M) | (330.6M) | (451.8M) | (561.8M) | (455.5M) | (432.8M) | |
| Ebit | (226.7M) | (337.7M) | (439.7M) | (573.7M) | (430.1M) | (408.6M) | |
| Research Development | 191.6M | 260.9M | 295.9M | 379.6M | 413.5M | 434.1M | |
| Ebitda | (217.0M) | (328.9M) | (423.7M) | (556.0M) | (411.2M) | (390.6M) | |
| Total Operating Expenses | 240.1M | 337.6M | 456.0M | 600.9M | 677.9M | 711.8M | |
| Income Before Tax | (218.3M) | (419.2M) | (383.9M) | (577.8M) | (474.1M) | (450.4M) | |
| Total Other Income Expense Net | 8.5M | (88.6M) | 67.8M | (16.0M) | (18.6M) | (17.7M) | |
| Net Income | (218.0M) | (419.0M) | (383.6M) | (583.2M) | (481.4M) | (457.4M) | |
| Income Tax Expense | (234K) | (219K) | (367K) | 5.4M | 7.3M | 7.7M | |
| Net Income From Continuing Ops | (218.0M) | (419.0M) | (383.6M) | (583.2M) | (481.4M) | (457.4M) | |
| Net Income Applicable To Common Shares | (218.0M) | (419.0M) | (383.6M) | (583.2M) | (524.9M) | (498.6M) | |
| Tax Provision | (234K) | (219K) | (367K) | 5.4M | 7.3M | 7.7M | |
| Interest Income | 10.1M | 1.8M | 692K | 7.4M | 16.9M | 17.7M | |
| Net Interest Income | 8.8M | (106K) | (3.2M) | (43.1M) | (27.2M) | (25.8M) | |
| Reconciled Depreciation | 6.7M | 9.4M | 15.4M | 18.0M | 18.9M | 11.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.88) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.